PEACE 6 (Phase III)

Investigator physician: Dr Marine CLAUDIN

Randomized phase III trial aiming to evaluate whether administration of ¹⁷⁷Lu-PSMA-617 could improve disease management in men with de novo metastatic hormone-sensitive prostate cancer who are poor responders to standard treatment

Patients with de novo metastatic hormone-sensitive prostate cancer with serum PSA ≥ 0.2 ng/mL, 6 to 8 months after initiation of systemic therapy for mHSPC (i.e., with an unsatisfactory response to systemic therapy) in the absence of evidence of disease progression (including rising PSA)

The PEACE-6 Poor Responders trial is designed to study the efficacy and safety of ¹⁷⁷Lu-PSMA-617 in combination with standard of care (SOC) in patients with mCRPC with PSA levels ≤ 0.2 ng/ml, 6 to 8 months after initiation of systemic therapy for mCRCS.

Treatment: ¹⁷⁷Lu-PSMA-617
Study status: Recruiting
Clinical Trial number: NCT06496581
Funding: